U.S. markets closed

Vincerx Pharma, Inc. (VINC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
15.45+0.16 (+1.05%)
At close: 4:00PM EDT
15.45 0.00 (0.00%)
After hours: 04:00PM EDT

Vincerx Pharma, Inc.

260 Sheridan Avenue
Suite 400
Palo Alto, CA 94306
United States
650 800 6676

Full Time Employees28

Key Executives

NameTitlePayExercisedYear Born
Dr. Ahmed M. HamdyFounder, Chairman & CEO622.05kN/A1965
Dr. Raquel E. IzumiFounder, Pres, COO, Sec. & Director652.84kN/A1970
Mr. Alexander A. Seelenberger M.B.A., MBAChief Financial Officer405.46kN/A1979
Mr. Stuart Hwang Ph.D.Chief Bus. Officer & FounderN/AN/AN/A
Mr. Tom C. ThomasFounder, Gen. Counsel & Chief Legal OfficerN/AN/A1960
Dr. John C. Byrd M.D.Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Dr. Xiaoming Zhang Ph.D.Chief Technical OfficerN/AN/A1964
Dr. Hans-Georg Lerchen Ph.D.Chief Scientific OfficerN/AN/AN/A
Dr. Hermes Garban M.D., Ph.D.Chief Medical OfficerN/AN/A1968
Dr. David Nganele M.B.A., Ph.D.Head of Early Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in Phase I clinical trials to treat solid tumors. Its preclinical stage product candidates include VIP217 for solid tumors; VIP236 to treat multiple solid tumors; VIP943 for the treatment of leukemia and myelodysplastic syndrome; and VIP924 for treating B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Corporate Governance

Vincerx Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.